First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)

BACKGROUND: MYB is a transcription factor that is overexpressed in colorectal cancer (CRC) and also a driver mutation in adenoid cystic carcinoma (AdCC). Therefore, the MYB protein is an ideal target to vaccinate against to aid recruitment of tumour infiltrating lymphocytes (TILs) against these tumo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Contemp Clin Trials Commun
Main Authors: Pham, Toan, Pereira, Lloyd, Roth, Sara, Galletta, Laura, Link, Emma, Akhurst, Tim, Solomon, Ben, Michael, Michael, Darcy, Phillip, Sampurno, Shienny, Heriot, Alexander, Ramsay, Robert, Desai, Jayesh
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6804811/
https://ncbi.nlm.nih.gov/pubmed/31650066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.conctc.2019.100409
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados